Skip to content

3D-printed multi-channel cylinder applicator compared with single-channel cylinder applicator in the dosimetry, efficacy and toxic side effects of close treatment for cervical cancer patients with middle and lower 1/3 vaginal lesions

3D-printed multi-channel cylinder applicator compared with single-channel cylinder applicator in the dosimetry, efficacy and toxic side effects of close treatment for cervical cancer patients with middle and lower 1/3 vaginal lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070228
Enrollment
Unknown
Registered
2023-04-06
Start date
2023-04-06
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Dosimetry comparision of 3D printed multi channel group and virtual single channel group:No
The comparision of dosimetry and efficacy and side effects between 3D printed multi channel group and actual single channel group:No

Sponsors

Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, = 10mm, CT scan short diameter of lymph node lesion >= 15mm); 6. No contraindications for close treatment; 7. No serious medical complications; 8. Patients voluntarily joined the study and signed informed consent with good compliance and follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with local cervical mass larger than 4 cm; 2. Patients with parauuterine invasion up to the pelvic wall, or with definite pathological evidence of vesicorectal invasion; 3. Severe vaginal stenosis or too short to implant a multi-channel transmitter; 4. Those who have a history of psychotropic drug abuse and cannot get rid of it or have mental disorders; 5. The investigator determines other conditions that may affect the conduct of the clinical study and the determination of the study results.

Design outcomes

Primary

MeasureTime frame
HR-CTV D90;the rectum dose of D2cc;the rectum dose of D1cc;the bladder dose of D2cc;the bladder dose of D1cc;the sigmoid colon dose of D2cc;the sigmoid colon dose of D1cc;Response Evaluation in Solid Tumors;Acute genitourinary toxici-ties;acute proctitis;

Secondary

MeasureTime frame
Overdose index;Dose nonuniformity index;Dose homogeneity index;Conformity index;the sigmoid colon dose of D0.01cc;the sigmoid colon dose of D0.1cc;the bladder dose of D0.01cc;the bladder dose of D0.1cc;the rectum dose of D0.01cc;the rectum dose of D0.1cc;

Countries

China

Contacts

Public ContactJiehui Li

Affiliated Hospital of Guizhou Medical University

lijiehui@gmc.edu.cn+86 151 8519 1569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026